Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Showing 20 of 27412 trials
Model-based Electrical Brain Stimulation
NCT05327387
Recruiting
Conditions Medication Refractory Epilepsy Patients ...
Phase NA
Enrollment 25
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Neuropsychiatric disorders are a leading cause of disability worldwide with depressive disorders being one of the most disabling among them. Also, millions of patients do not respond to current medications or psychotherapy, which makes it critical to find an alternative therapy. Applying electrical stimulation at various brain targets has shown promise but there is a critical need to improve efficacy. Given inter- and intra-subject variabilities in neuropsychiatric disorders, this study aims to enable personalizing the stimulation therapy via i) tracking a patient's own symptoms based on their neural activity, and ii) a model of how their neural activity responds to stimulation therapy. The study will develop the modeling elements needed to realize a model-based personalized system for electrical brain stimulation to achieve this aim. The study will provide proof-of-concept demonstration in epilepsy patients who already have intracranial electroencephalography (iEEG) electrodes implanted for their standard clinical monitoring unrelated to this study, and who consent to being part of the study.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: model-based electrical brain stimulation — Electrical pulse train stimulation delivered to medication refractory epilepsy patients with electrodes already implanted based on clinical criteria for standard monitoring unrelated to this study. The delivery of the electrical brain stimulation can be guided by neural biomarkers of symptom levels computed from ongoing neural activity and by input-output models of neural response to stimulation therapy. The parameters of electrical stimulation will be constrained to be within clinically safe ranges.

Primary Outcomes

  • Decoded depression symptom ratings based on neural activity (5-10 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-02-08
Completion: 2026-03-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern California
Collaborators: University of California, San Francisco, National Institute of Mental Health (NIMH)
Principal Investigators:
  • Maryam M Shanechi, PhD (PRINCIPAL_INVESTIGATOR) - University of Southern California
Contact Information
Study Contact:
Maryam M Shanechi, PhD
213-740-1377
shanechi@usc.edu
HyeongChan Jo, PhD
hj_380@usc.edu
Interventions
  • Other: model-based electrical brain stimulation — Electrical pulse train stimulation delivered to medication refractory epilepsy patients with electrodes already implanted based on clinical criteria for standard monitoring unrelated to this study. The delivery of the electrical brain stimulation can be guided by neural biomarkers of symptom levels computed from ongoing neural activity and by input-output models of neural response to stimulation therapy. The parameters of electrical stimulation will be constrained to be within clinically safe ranges.
Study Locations (2 sites)
University of Southern California, Los Angeles, California 90089 United States
University of California, San Francisco, San Francisco, California 94143 United States
Eligibility Criteria
Inclusion Criteria: * Patients being evaluated for surgical treatment of medication refractory epilepsy and brain tumors will be studied. ONLY patients with electrodes implanted based on clinical criteria to locate their seizure focus will be studied. Most patients are healthy adults, outside of their epilepsy and/or brain tumor. * Subjects \>= 18 are only included in this study. * All patients with the above conditions and with implanted electrode arrays who are willing to participate and able to cooperate and follow research instructions will be recruited. However, analysis of research recording data will focus on those subjects with an IQ \>= 80, with no impairments of reading, naming, or articulation (to minimize confounds such as abnormal language processing that may affect their self-reporting with the questionnaire), and with no cerebral pathology affecting the cortical regions from which recordings are made. Exclusion Criteria: * Subjects \< 18 years old will be excluded from this study due to the high concordance of developmental disorders (cognitive and language-related) in pediatric epilepsies. * There will be no involvement of special classes of subjects, such as fetuses, neonates, pregnant women, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations. * Patients who are unable to give informed consent due to a brain disorder will be excluded from the study, as it is very likely that they would be unable to carry out the tasks demanded by the study.
Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression
NCT07476534
Not yet recruiting
Conditions Solid Tumor Malignancies
Phase Not Applicable
Enrollment 100
Locations 0 sites
Compensation Compensation varies
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Identifying and validating molecular biomarkers associated with tumor-related anxiety and depression. By integrating psychological assessment data from clinical tumor patients with molecular detection results, and utilizing clinically accessible samples such as tumor tissues and sera from clinical cohorts, this study aims to clinically validate the tumor-derived proteins previously identified by our team as having potential regulatory roles. The goal is to clarify the clinical value of tumor-derived proteins as molecular biomarkers for tumor-related anxiety and depression, providing a molecular basis for early screening and risk stratification. Alternatively, it seeks to establish a tumor-related anxiety and depression risk assessment model based on the expression levels of tumor-derived proteins, offering a reference for the precise identification and targeted intervention of psychological disorders in tumor patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Clear tumor-derived protein-related tumor-related anxiety and depression molecular markers (2026.03-2026.12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Not yet recruiting
Start Date: 2026-03-01
Completion: 2026-12-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital of Xinxiang Medical College
Contact Information
Study Contact:
姬 颖 华, Graduate student
03734402543
54234317@qq.com
Interventions
N/A
Eligibility Criteria
Inclusion Criteria: 1. Patients with solid tumors aged ≥18 years and an expected survival period of ≥3 months; 2. Patients who meet clinical diagnostic criteria and are pathologically/histologically confirmed as having solid tumors, including liver cancer patients (diagnosable by imaging); 3. Patients who can complete standardized stratified assessments for tumor-related anxiety and depression, and are able to cooperate with researchers in completing psychological scales such as the Self-Rating Anxiety Scale (SAS) and the Self-Rating Depression Scale (SDS). They have not received any anti-anxiety/depression medications, professional psychological counseling, or psychiatric interventions before scale assessment; 4. Patients with clear consciousness, normal language communication, comprehension, and cognitive abilities, without a history of psychiatric disorders, and who can independently provide feedback on research-related information and cooperate with follow-up; 5. Patients who voluntarily participate in the study, fully understand the research objectives, procedures, potential risks, and benefits, and have signed a written informed consent form; 6. Patients who can cooperate in completing the required laboratory tests (complete blood count, blood biochemistry, coagulation function, etc.) and clinical data collection before and during the perioperative period to ensure the completeness of research data. Exclusion Criteria: 1. Pregnant or lactating women; 2. Patients aged \<21 years at first visit and with an expected survival period of \<3 months; 3. Patients who have previously received anti-anxiety/depression medications or professional psychological interventions; 4. Patients with a history or current diagnosis of psychiatric disorders, including schizophrenia, bipolar disorder, severe cognitive dysfunction, mental retardation, or those who cannot cooperate with SAS/SDS scale assessment or have contraindications to scale evaluation; 5. Patients with severe organ dysfunction or severe underlying diseases, including: liver failure (Child-Pugh C grade), renal failure (serum creatinine \>250 μmol/L or \>2.83 mg/dL), New York Heart Association (NYHA) Class IV heart failure, active pulmonary tuberculosis, HIV infection, etc. (to be determined); 6. Patients with contraindications to tumor tissue or blood sample collection, including coagulation disorders (INR \>1.5, platelets \<50×10⁹/L), severe bleeding tendency, or surgical specimens that cannot meet detection requirements (e.g., \>50% necrotic tissue, insufficient tissue amount); 7. Patients with emotional abnormalities due to non-tumor factors, including hyperthyroidism/hypothyroidism, severe malnutrition, chronic wasting diseases, or psychological stress disorders; 8. Patients who have undergone non-tumor-related surgical procedures, enteral/parenteral nutrition support within the past 1 month, or have clinical symptoms such as gastrointestinal mechanical obstruction, intractable vomiting, ascites, significant edema, or large pleural effusion; 9. Patients who are planned or currently using medications that may affect emotional assessment or protein expression detection during the study, including: long-term oral corticosteroids, 5-HT receptor agonists/antagonists (SSRIs, etc., even short-term use within 2 weeks before sampling is excluded), antipsychotic drugs, or gestagenic synthetic steroid derivatives (short-term inhaled/local use of steroids or intermittent use of inhaled bronchodilators are excluded); 10. Patients with incomplete clinical data, inability to cooperate with research-related follow-up and testing, or those who refuse to sign the informed consent form or have poor compliance.
Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity
NCT07136714
Recruiting
Conditions Major Depressive Disorder
Phase PHASE4
Enrollment 116
Locations 1 sites
Compensation Phase 4: Typically $100-$500
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of semaglutide once-weekly vs. placebo on depressive symptoms in 116 patients with Major Depressive Disorder (MDD) and co-existing overweight or obesity. The treatment will be an add-on treatment to the patient's usual medication. The investigators hypothesize that adjunctive treatment with semaglutide, will lead to a significant improvement in mood compared to placebo in patients with MDD and overweight or obesity. The primary endpoint is the change in depressive symptoms measured as difference in the 12-item self-report mood questionnaire Major Depression Inventory (MDI) from start to follow-up after 26 weeks. The MDI measures the extent to which symptoms of depression have been present in the past two weeks.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Semaglutide Injectable Product — Semaglutide (Wegovy) once-weekly injection s.c
  • Drug: Placebo — Placebo (BD Posiflush) once-weekly injection s.c

Primary Outcomes

  • Change in depressive symptoms (From baseline to 26 weeks of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-09-11
Completion: 2027-09
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 116 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nordsjaellands Hospital
Principal Investigators:
  • Maj Vinberg, MD, PhD, DMSc (PRINCIPAL_INVESTIGATOR) - Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Contact Information
Study Contact:
Maj Vinberg, MD, DMSc
+ 45 38 64 32 27
maj.vinberg@regionh.dk
Christoffer Stanislaus, MD, ph.d.-student
Christoffer.stanislaus@regionh.dk
Interventions
  • Drug: Semaglutide Injectable Product — Semaglutide (Wegovy) once-weekly injection s.c
  • Drug: Placebo — Placebo (BD Posiflush) once-weekly injection s.c
Study Locations (1 sites)
Mental Health Centre North Zealand, Hillerød, Denmark 3400 Denmark
Eligibility Criteria
Inclusion Criteria: 1. Informed oral and written consent. 2. Diagnosed with unipolar disorder according to the criteria of ICD10 (International Classification of Diseases, World Health Organization (WHO)) or the DSM-V (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, the American Psychiatric Association 3. Hamilton Depression Rating Scale, 17-items (HDRS-17)47 score ≥14, 4. Age 18 years to 65 years (both included) 5. Body mass index (BMI) ≥27 kg/m2 6. Able to speak and understand Danish Exclusion Criteria: 1. Any significant medical disorder or conditions that contraindicate the investigational drug, e.g., pregnancy, presence of known allergy GLP-1 receptor agonists, severe neurological disorder, on-going drug, or alcohol abuse 2. Coercive measures 3. Females of childbearing potential who are pregnant, breast-feeding or have the intention of becoming pregnant within the next 9 months (26 weeks plus two months after discontinuation of semaglutide), or are not using contraceptives (during the whole study period) considered as highly effective (combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) intrauterine device - IUD, IUS, bilateral tubal occlusion, vasectomised partner, sexual abstinence) 4. Patients treated with corticosteroids or other hormone therapy (except oestrogens). 5. Any active substance abuse or dependence (except for nicotine) 6. Impaired hepatic function (plasma liver transaminases \>2 times upper normal limit). 7. Impaired renal function (serum creatinine \>150 μmol/l) 8. Cardiac problems defined as decompensated heart failure (NYHA class III/IV), unstable angina pectoris, and/or myocardial infarction within the last 12 months 9. Hypertension with systolic blood pressure \>180 mmHg or diastolic blood pressure \>100 mmHg 10. Impaired pancreatic function (acute or chronic pancreatitis and/or plasma amylase \>2 times upper normal limit). Receiving any experimental or pre-marketing drug within the last 3 months 11. Use of diabetes medication or weight-lowering pharmacotherapy e.g. semagultid within the preceding 3 months 12. Known type 1 and 2 diabetes or HbA1c\>48mmol/l 13. Suicidal behaviour as judged by the investigator and based on clinical evaluation. At all contact with patient attendance (please see Table 1) possible suicidality will be evaluatedaccording to the guidelines. If the patient is evaluated as suicidal, the person will be excluded from the study and evaluated by a senior consultant in psychiatry, who will take further action. 14. Any condition that the investigator feels would interfere with trial participation.
Nano-Learning for Improving Compliance Among Older Adults With Sarcopenia
NCT07185763
Active, positions filled
Conditions Learning; Lack of (Specific), Depression...
Phase NA
Enrollment 180
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Empirical evidence suggests that the use of short videos is associated with decreased feelings of loneliness and social isolation, thereby reducing depression among older adults . Platforms that allow users to showcase aspects of their own lives also serve as a significant avenue for achieving "happiness in old age" and enhancing social interactions with acquaintances . Therefore, this study aims to provide robust evidence on the effectiveness of nano-learning interventions, particularly in the context of sarcopenia, where addressing physical and psychological well-being has become increasingly critical among this cohort.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Nano-Learning interventional program — AI-based Nano-learning videos involves designing ultra-short, single-focus lessons (not exceeding 2 minutes). Each session was delivered in form of some videos.

Primary Outcomes

  • A Composite Physical Function (CPF) Scale (2 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Active, positions filled
Start Date: 2025-09-07
Completion: 2026-02-25
Eligibility
Age: 58 Years
Sex: ALL
Volunteers: true
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alexandria University
Principal Investigators:
  • rasha eweida (PRINCIPAL_INVESTIGATOR) - Damanhour University
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Behavioral: Nano-Learning interventional program — AI-based Nano-learning videos involves designing ultra-short, single-focus lessons (not exceeding 2 minutes). Each session was delivered in form of some videos.
Study Locations (1 sites)
Faculty of Nursing, Alexandria, 21523 Egypt
Eligibility Criteria
Inclusion Criteria: * Participants were eligible if they were 60 years or older, * had a diagnosis of sarcopenia based on a cut-off score of ≥3 of the Sarcopenia Geriatric Scale (SARCO-GS) (Rosas-Carrasco, 2023), * able to communicate effectively, and provided informed consent. Exclusion Criteria: * Exclusion criteria encompassed severe cognitive impairment, debilitating chronic conditions, or unstable medical status that could hinder participation. * Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA), with a cutoff score of 25 or below used to exclude participants (Nasreddine, 2005).
Evaluation of Depression Screening Methods Administered by Registered Nurses in Chronic Hemodialysis Patients
NCT07651436
Recruiting
Conditions Depressive Disorders, End-stage Chronic ...
Phase NA
Enrollment 450
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Hemodialysis is a vital replacement therapy for patients with end-stage chronic kidney disease, but it imposes a heavy, demanding, and prolonged management, associated with a significant deterioration in quality of life. Hemodialysis patients are exposed to numerous physical, organizational, and social constraints, including repeated and prolonged sessions at the center, dietary and fluid restrictions, chronic fatigue, and frequent comorbidities. Therefore, depressive disorders in hemodialysis patients represent a major public health issue. The literature reports a high prevalence of depressive symptoms among hemodialysis patients, ranging from 22% to 60%, significantly higher than that observed in the general population. These disorders are associated with a significant deterioration in quality of life, increased hospitalizations, lower therapeutic adherence, an increased risk of suicide, and excess mortality. Despite these important clinical consequences, depressive disorders often remain underdiagnosed in hemodialysis. Current guidelines, including those from the Haute Autorité de Santé (HAS), emphasize the importance of regular quality of life assessments in patients with chronic kidney disease and recommend the use of validated questionnaires. However, they do not formalize a specific operational strategy for screening depressive disorders in routine hemodialysis practice, contributing to their under-evaluation. The gold standard diagnosis of depressive disorders relies on a structured psychiatric interview, which is difficult to reconcile with the organizational constraints of dialysis centers. Standardized self-assessment tools, such as the Hospital Anxiety and Depression Scale (HADS), particularly its depression subscale (HADS-D), have been widely used. The HADS-D has the advantage of excluding somatic symptoms and has been validated in hemodialysis patients. However, self-assessment relies on the patient's ability to express their subjective experience. Thus, the self-administration of standardized questionnaires in these patients is often challenging due to their age, comorbidities, fatigue, and functional limitations, often necessitating the intervention of healthcare staff. In contrast, registered nurses (IDE) working in hemodialysis possess longitudinal clinical knowledge of patients, acquired over repeated sessions, which can serve as a relevant lever for rapid and standardized screening of depressive symptoms. To date, the diagnostic performance of structured nursing hetero-evaluation remains poorly documented. The IDE-3D study aims to evaluate the ability of nurses to identify depressive symptoms in hemodialysis patients using structured tools, comparing the nursing hetero-evaluation of the HADS-D with the self-assessment conducted by the patient. It is part of a pragmatic approach aimed at improving the screening of depressive disorders in hemodialysis, structuring the care pathway, and enhancing the integration of mental…

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: evaluate the psychometric performance of different modalities of hetero-assessment of depressive symptoms by nurses — Interventional study with minimal risks and constraints. The main objective is to evaluate the psychometric performance of different modalities of hetero-assessment of depressive symptoms by nurses in patients receiving in-center hemodialysis, compared to reference self-assessment tools completed by the patients.

Primary Outcomes

  • The diagnostic performance of the hetero-assessment (From enrollment to the end of intervention (between one week and 2 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-26
Completion: 2028-10
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 450 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Annecy Genevois
Collaborators: GIRCI Auvergne Rhone-Alpes, SFNDT - Société Francophone de Néphrologie, Dialyse et Transplantation
Principal Investigators:
  • Cécile Herlet (PRINCIPAL_INVESTIGATOR) - Centre Hospitalier Annecy Genevois
Contact Information
Study Contact:
Alexandra Rippoz
0033 4 85522120
arippoz@ch-annecygenevois.fr
DRCI CH Annecy Genevois
drci.promotion@ch-annecygenevois.fr
Interventions
  • Other: evaluate the psychometric performance of different modalities of hetero-assessment of depressive symptoms by nurses — Interventional study with minimal risks and constraints. The main objective is to evaluate the psychometric performance of different modalities of hetero-assessment of depressive symptoms by nurses in patients receiving in-center hemodialysis, compared to reference self-assessment tools completed by the patients.
Study Locations (2 sites)
Centre Hospitalier Annecy Genevois, Annecy, 74370 France
Centre Hospitalier Métropole Savoie, Chambéry, 73000 France
Eligibility Criteria
Inclusion Criteria: * Patient informed about the nature, process, and objectives of the study and having signed a free and informed consent to participate, * Patient treated with conventional hemodialysis for at least 3 months and currently undergoing dialysis 3 times a week, * Patient covered by the french national social welfare Exclusion Criteria: * Patient suffering from dementia * Pregnant or breastfeeding patient * Patient unable to understand the French language both orally and in writing, - making self-assessment impossible * Patient currently participating in another interventional research protocol or in an exclusion period from such research * Patient who has already been included in this study * Patient under guardianship, curatorship, or placed under judicial protection.
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964
Recruiting
Conditions Bipolar Depression
Phase PHASE3
Enrollment 384
Locations 68 sites
Compensation Phase 3: Typically $200-$1,000
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Lumateperone — Lumateperone administered orally, once daily.
  • Drug: Placebo — Matching placebo administered orally, once daily.

Primary Outcomes

  • Children's Depression Rating Scale-Revised (CDRS-R) (Week 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-05-14
Completion: 2031-10-31
Eligibility
Age: 10 Years
Sex: ALL
Volunteers: false
Enrollment: 384 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Intra-Cellular Therapies, Inc.
Principal Investigators:
  • Intra-Cellular Therapies, Inc. Clinical Trial (STUDY_DIRECTOR) - Intra-Cellular Therapies, Inc.
Contact Information
Study Contact:
Study Contact
844-434-4210
Participate-In-This-Study1@its.jnj.com
Interventions
  • Drug: Lumateperone — Lumateperone administered orally, once daily.
  • Drug: Placebo — Matching placebo administered orally, once daily.
Study Locations (68 sites)
Harmonex Neuroscience Research, Dothan, Alabama 36303 United States
Pillar Clinical Research, LLC, Little Rock, Arkansas 72204 United States
Advanced Research Center, Inc, Anaheim, California 92805 United States
Inland Psychiatric Medical Group Inc, Redlands, California 92373 United States
UC Davis Health System, Sacramento, California 95817 United States
University of California San Diego Medical Center, San Diego, California 92103 United States
Next Level Clinical Trials, LLC, West Covina, California 91790 United States
MCB Clinical Research Centers LLC, Colorado Springs, Colorado 80910 United States
Royal Palm Clinical Research, Fort Myers, Florida 33901 United States
United Research Institute, Hialeah, Florida 33012 United States
Eligibility Criteria
Inclusion Criteria: 1. Able to provide consent as follows: * The Legally Authorized Representative (LAR) must provide written, informed consent. * The patient must provide written assent; 2. Male or female patients 10 to 17 years of age, inclusive; 3. Have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of bipolar I or bipolar II disorder with a current MDE without psychosis as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL); 4. Subject has a lifetime history of at least one manic or hypomanic episode. 5. Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration; 6. CDRS-R total score ≥ 45 with ≥ 5 on Item 11 (depressed feelings) at Screening and Baseline; 7. Young Mania Rating Scale (YMRS) score ≤ 15 (with YMRS Item 1 \[elevated mood\] score ≤ 2) at Screening and Baseline. Exclusion Criteria: 1. Has a primary psychiatric diagnosis other than bipolar I or bipolar II disorder. Exception includes: * Attention deficit hyperactivity disorder (ADHD). If a subject is taking medications for ADHD, they must have been on a stable treatment regimen of these medication(s) for 30 days prior to screening and the treatment regimen is expected to remain stable throughout the study. 2. Intellectual disability based on Investigator opinion and DSM-5 criteria 3. Patient has been hospitalized for a bipolar manic episode within the 30 days prior to randomization; 4. Demonstrates a ≥ 25% decrease (improvement) in the CDRS-R total score between Screening and Baseline visits, or the CDRS-R is below 45 at Baseline; 5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his/her participation in the study or 1. At Screening, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 since the Screening Visit; 2. At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening; or 3. At Screening or Baseline, scores \> 3 on Item 13 (suicidal ideation) on the CDRS-R; or 4. The patient is considered to be an imminent danger to him/herself or others.
Community Health Worker Implementation of Transdiagnostic Evidence-based Mental Health Intervention for Spanish-speaking Latine Parents
NCT07390630
Not yet recruiting
Conditions Depression, Anxiety, Traumatic Stress
Phase NA
Enrollment 52
Locations 0 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if it is doable for community health workers (CHWs) to deliver a mental health intervention to Spanish-speaking Latine parents experiencing anxiety, depression, and/or traumatic stress. The main questions it aims to answer are (1) Is it doable for CHWs to deliver the mental health intervention and for Latine parents to participate in the intervention, and (2) does the CHW-delivered intervention work in reducing Latine parents' mental health symptoms. Researchers will compare Latine parents receiving the intervention to Latine parents not receiving the intervention to see if the CHW-delivered intervention works to improve mental health symptoms. Participants will: * Participate in up to 14 weekly 1-hour sessions of the mental health intervention delivered by a CHW. They will be randomized to receive the intervention immediately or after a 5-month delay. * Participants will complete questionnaires about their symptoms, family and child functioning, as well as about how doable, acceptable, and appropriate they found the intervention * Participants will also complete a recorded interview about their experience in the intervention

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Common Elements Treatment Approach (CETA) — CETA is a transdiagnostic evidence-based treatment (EBT) designed to be implemented in low-resource settings and delivered by lay providers with little to no prior mental health training (i.e., CHWs). CETA consists of 11 modules that address the most common mental health disorders, including depression, anxiety, and post-traumatic stress. Modules are based on common elements of EBT, and include topics of psychoeducation, behavioral activation, relaxation, cognitive restructuring, exposures, safety planning, and substance use reduction. Designed with non-specialists in mind, CETA materials follow a simple, concrete format, with a 1-5 page "manual" section and 1-2 page "steps sheet" for each module that includes goals, example wording, and guidance for in-session use during implementation. CETA has demonstrated effectiveness in RCTs around the world, but has yet to be examined in the US in the context of CHW implementation.

Primary Outcomes

  • Patient engagement (Through study completion; over the course of approximately up to 5 months of participant participation)
  • Fidelity (Completed after each CETA session through study completion, over the course of approximately up to 5 months of participant participation)
  • Patient intervention retention (Through study completion; over the course of approximately up to 5 months of participant participation)
  • Patient control retention (Through study completion; over the course of approximately up to 5 months of participant participation)
  • Patient assessment completion (Through study completion; over the course of approximately up to 5 months of participant participation)
  • Patient intervention feasibility, acceptability, & appropriateness (Patients will complete the mhIST immediately after their last intervention session)
  • Provider intervention feasibility, acceptability, & appropriateness (After approximately 2 years of intervention delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2027-02
Completion: 2029-03
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Illinois at Chicago
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD), Sinai Urban Health Institute
Contact Information
Study Contact:
Erika L Gustafson, PhD
312-355-0626
gustafs6@uic.edu
Interventions
  • Behavioral: Common Elements Treatment Approach (CETA) — CETA is a transdiagnostic evidence-based treatment (EBT) designed to be implemented in low-resource settings and delivered by lay providers with little to no prior mental health training (i.e., CHWs). CETA consists of 11 modules that address the most common mental health disorders, including depression, anxiety, and post-traumatic stress. Modules are based on common elements of EBT, and include topics of psychoeducation, behavioral activation, relaxation, cognitive restructuring, exposures, safety planning, and substance use reduction. Designed with non-specialists in mind, CETA materials follow a simple, concrete format, with a 1-5 page "manual" section and 1-2 page "steps sheet" for each module that includes goals, example wording, and guidance for in-session use during implementation. CETA has demonstrated effectiveness in RCTs around the world, but has yet to be examined in the US in the context of CHW implementation.
Eligibility Criteria
INCLUSION criteria for PATIENT participants are: * 18 years or older * Identifies as Latine * Is a caregiver to a child 18 years or younger old living in the same household * Preference for Spanish services * Symptom scores in the moderate range for depression, anxiety, and/or PTSD (based on Computerized Adaptive Tests for Mental Health (CAT-MH)) EXCLUSION criteria for PATIENT participants: * Presence of mania symptoms in the mild range or higher (based on CAT-MH responses) * Presence of psychosis symptoms in mild range or higher (based on CAT-MH responses) * Active suicidal ideation (based on CAT-MH responses) * Depression, anxiety, or PTSD symptoms in the severe range (based on CAT-MH responses) * Currently receiving psychotherapy services
The Effects of Yoga Exercises in Overweight and Obese Women
NCT06979830
Not yet recruiting
Conditions Overweight and Obese Women
Phase NA
Enrollment 50
Locations 0 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Obesity has been defined by the World Health Organization (WHO) as an abnormal accumulation of fat in the body that negatively affects health and has been reported to be the most significant public health problem of the 21st century. In the late 1990s, WHO described obesity as a "global epidemic." This epidemic and its associated complications cause the death of 2.8 million adults annually. Additionally, obesity imposes a significant financial burden on countries' healthcare and social security systems. Therefore, obesity stands out as an issue that requires urgent preventive measures. Obesity is associated with various abnormalities in respiratory functions. Changes in respiratory system mechanics due to decreased lung volumes indicate a strong link between obesity and chronic respiratory diseases. Furthermore, obesity is a risk factor for conditions such as hypertension, cardiovascular diseases, and diabetes. Yoga is known to have numerous positive effects on health and can provide significant benefits, particularly in improving respiratory functions. Yoga is also an important tool for coping with stress, which can positively influence the respiratory system. It has been reported that yoga reduces the impact of stress on respiratory rate, promoting deep breathing and relaxation. Some studies on the effects of yoga on obesity have not reached significant conclusions. A study comparing the effects of Vinyasa and Hatha yoga on obesity management found that neither type had a significant effect on metabolism. These studies fail to fully explain the mechanism by which yoga affects obesity due to differences in yoga styles and their lack of standardization, variations in practice durations, and the differing characteristics of study populations. Furthermore, studies on obesity and yoga often have short intervention durations (an average of 8 weeks), with most involving 60-90 minute sessions conducted 1-2 times per week. Since longer-term studies are needed to better understand the relationship between obesity and yoga, this study aims to investigate the effects of yoga exercises on body composition, respiratory parameters, functional level, sleep quality, quality of life, and emotional state in overweight and obese women.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: yoga exercises — The yoga program, based on Hatha yoga content, will be conducted in groups of 10 participants, for 12 weeks, 3 days a week, at the same time each day (12:00-13:00), and will be administered by an experienced physiotherapist (Appendix 4). Before starting the training program, the exercise group will be given a one-week adaptation period, during which the exercises to be performed in three sessions per week will be taught. Participants in the exercise group who miss sessions for various reasons will be given an additional one-week period to make up for missed sessions. Participants who miss more than four sessions will be excluded from the study. Participants were informed in advance about any personal items they might need before each yoga session (such as towels, tissues, etc.) and were advised to bring their own. The yoga sessions were held in the sports hall of the Artvin Çoruh Dormitory, where the required equipment for yoga (e.g., mats, blocks) was provided. The yoga program was

Primary Outcomes

  • Forced Vital Capacity (FVC) (From enrollment to the end of treatment at twelve weeks)
  • Assessment of Dynamic Balance and Functional Level (Timed Up and Go Test) (From enrollment to the end of treatment at twelve weeks")
  • Body Mass Index (From enrollment to the end of treatment at twelve weeks)
  • Waist Circumference (From enrollment to the end of treatment at twelve weeks)
  • Hip Circumference (From enrollment to the end of treatment at twelve weeks)
  • Forced Expiratory Volume at One Second (FEV1) (From enrollment to the end of treatment at twelve weeks)
  • Peak Expiratory Flow (PEF) (From enrollment to the end of treatment at twelve weeks)
  • Maximum Mid-expiratory Flow 25-75% (MMEF25-75) (From enrollment to the end of treatment at twelve weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2025-06-01
Completion: 2025-10-01
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ondokuz Mayıs University
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Behavioral: yoga exercises — The yoga program, based on Hatha yoga content, will be conducted in groups of 10 participants, for 12 weeks, 3 days a week, at the same time each day (12:00-13:00), and will be administered by an experienced physiotherapist (Appendix 4). Before starting the training program, the exercise group will be given a one-week adaptation period, during which the exercises to be performed in three sessions per week will be taught. Participants in the exercise group who miss sessions for various reasons will be given an additional one-week period to make up for missed sessions. Participants who miss more than four sessions will be excluded from the study. Participants were informed in advance about any personal items they might need before each yoga session (such as towels, tissues, etc.) and were advised to bring their own. The yoga sessions were held in the sports hall of the Artvin Çoruh Dormitory, where the required equipment for yoga (e.g., mats, blocks) was provided. The yoga program was
Eligibility Criteria
Inclusion Criteria: * Age between 18-65 years * Body Mass Index (BMI) ≥ 25 * Waist circumference \> 88 cm * Waist-to-hip ratio \> 0.8 * Being literate, willing to participate, and signing the informed consent form * No mental disorders * No orthopedic or neurological conditions affecting balance * No history of surgical operations in the last 6 months Exclusion Criteria: * Pregnant and breastfeeding mothers * Participants following any diet program for obesity * Individuals with syndromic or endocrine-related obesity * Participants who regularly exercise * Individuals using psychiatric medication * Participants with a medical history that would prevent them from practicing yoga * Participants with cardiovascular diseases that prevent exercise * Participants with a yoga history within the last 6 months * Individuals with any complications of obesity requiring medication, such as Type 2 diabetes or Stage 2 hypertension * Experiencing pain over 7 on the Visual Analog Scale (VAS)
The Kunshan Elderly Health Study
NCT05141565
Active, positions filled
Conditions Cardiovascular Diseases, Diabetes Mellit...
Phase Not Applicable
Enrollment 5945
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The Kunshan Elderly Health Study (KEHS) is a community-based prospective cohort study of chronic disease, mortality and associated factors among elderly adults in Kunshan, Eastern China.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention — No intervention

Primary Outcomes

  • Incidence of chronic diseases (Trough study completion, an average of 10 years)
  • Mortality (Trough study completion, an average of 10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Active, positions filled
Start Date: 2021-05-17
Completion: 2032-12-31
Eligibility
Age: 65 Years
Sex: ALL
Volunteers: false
Enrollment: 5945 (ACTUAL)
Sponsor & Investigators
Lead Sponsor: Soochow University
Collaborators: Kunshan Center for Disease Control and Prevention, Suzhou Center for Disease Control and Prevention
Principal Investigators:
  • Hui Zuo, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR) - Soochow University
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Other: No intervention — No intervention
Study Locations (1 sites)
Kunshan Center for Disease Control and Prevention, Kunshan, Jiangsu 215301 China
Eligibility Criteria
Inclusion Criteria: * Locally registered-residents in Kunshan * Aged 65 years or above * Voluntary agreement to participate in the study (with written informed consent) Exclusion Criteria: * Patients with stroke, coronary heart disease or cancer * Patients with severe physical or mental illness * People unable to complete the survey
Study on the Correlation Between Metabolomics and Anxiety and Depression in Bronchiectasis
NCT07291167
Not yet recruiting
Conditions Bronchiectasis
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Bronchiectasis is a common lung disease. Approximately 20-40% of patients with bronchiectasis experience comorbid anxiety and depression. Multiple studies have now demonstrated that anxiety and depression are associated with an increased risk of disease exacerbation in these individuals. Therefore, this study aims to collect data on anxiety and depression status, disease exacerbation frequency, hospitalisation rates, and mortality among participants diagnosed with bronchiectasis. Concurrently, biological samples including blood, sputum, and stool will be obtained. Through metabolomics analysis, we will investigate the expression of anxiety and depression-related metabolic pathways and identify corresponding biomarkers to explore their role in the progression of bronchiectasis.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: inapplicable — This study is observational in nature and did not involve any intervention measures.

Primary Outcomes

  • Frequency of acute exacerbations of bronchiectasis (up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Not yet recruiting
Start Date: 2025-12-20
Completion: 2030-12-31
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Contact Information
Study Contact:
Xiaorong Wang
+86 18627195231
rong-100@163.com
Jianping Song
+86 15623201915
songjianpingxh@163.com
Interventions
  • Other: inapplicable — This study is observational in nature and did not involve any intervention measures.
Study Locations (1 sites)
Wuhan Union Hospital,China, Wuhan, Hubei 430030 China
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Participants' pulmonary imaging findings and clinical presentation met the diagnostic criteria for bronchiectasis * Clinically stable (no antibiotics or oral corticosteroids within 4 weeks prior to enrolment); * Patients who are willing to sign the consent form and participate in the study. Exclusion Criteria: * Age \<18 years * Does not meet the diagnostic criteria for bronchiectasis * Participants with cystic fibrosis or previous lung transplantation * Participants who are unable to cooperate with the study due to dysfunction of vital systems such as heart, brain, liver, and kidneys, or who are unable to participate in the study due to comorbid serious diseases * Participants with active disorders, including active tuberculosis, active allergic bronchopulmonary aspergillosis, active nontuberculous mycobacterial infection and malignancy or secondary traction bronchiectasis associated with pulmonary fibrosis * Pregnant or lactating females * Who are not able to provide informed consent or who refuse to participate in the clinical study
The Impact of Playing Tetris on Migrants' Mental Health
NCT06773338
Recruiting
Conditions Post-traumatic Stress Disorder (PTSD), A...
Phase NA
Enrollment 300
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study examines if playing Tetris prevents the development of Post-traumatic stress disorder or related anxiety and depressive symptoms. The investigators recruit 300 participants in total in Greece and in the Netherlands. The participants are immigrants who have applied for asylum at any point in the past. The participants are asked to answer three questionnaires (on Post-traumatic stress disorder, related anxiety and depressive symptoms, and post-migration living difficulties) on a recurring basis - once every 4 weeks, 12 times in total. Half of the participants (treatment group) are randomly selected to play Tetris after completing the questionnaires. Participants in the treatment group are instructed to play Tetris for at least 15 minutes while trying to remember bad things that recently happened to them. Tetris is administered at three instances and participants in the treatment group are encouraged to play Tetris in case of experiencing any traumatic events or having any intrusive memories during the course of the study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Tetris — Randomly selected participants (migrants) are asked to play Tetris for at least 15 minutes on several occasions. These participants are asked while playing Tetris to try and remember bad events that recently happened to them. The participants play the classic version of the Tetris game directly on their mobile phone.
  • Other: No intervention — Participants do not receive any intervention.

Primary Outcomes

  • Post-traumatic stress disorder (From enrolment to the end of the study (40 weeks))
  • Anxiety and depression symptoms (From enrolment to the end of the study (40 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-17
Completion: 2025-12-07
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: true
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tilburg University
Collaborators: Stichting tot steun VCVGZ
Contact Information
Study Contact:
Mario Braakman, Prof.
+31629514366
Mario.Braakman@tilburguniversity.edu
Tihomir Sabchev, Dr.
t.y.sabchev@tilburguniversity.edu
Interventions
  • Behavioral: Tetris — Randomly selected participants (migrants) are asked to play Tetris for at least 15 minutes on several occasions. These participants are asked while playing Tetris to try and remember bad events that recently happened to them. The participants play the classic version of the Tetris game directly on their mobile phone.
  • Other: No intervention — Participants do not receive any intervention.
Study Locations (2 sites)
Upinion (online), The Hague, NL 2511 CJ Greece
Upinion/the humanity Hub, The Hague, NL 2511 CJ Netherlands
Eligibility Criteria
Inclusion Criteria: * Arabic-speaking immigrants of any gender who have applied for asylum in Greece or in the Netherlands, regardless of the outcome of their asylum application and their current residency status (rejected asylum seekers, recognized refugees, undocumented migrants). Exclusion Criteria: * Minors (under the age of 18).
Evaluating the Impact of Digital Behavioral Interventions to Address Insomnia and Depression in Breast Cancer Survivors Using an Adaptive Design
NCT07721064
Not yet recruiting
Conditions Insomnia, Depression
Phase NA
Enrollment 747
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Co-occurring symptoms of insomnia and depression is very common in breast cancer survivors, and it is critical that scalable and easily accessible digital behavioral interventions are made available. Digital health interventions are scalable and accessible. Moreover, behavioral digital interventions have been shown to be effective in reducing symptoms of insomnia and depression, respectively, in breast cancer survivors, suggesting strong potential for public impact, though their potential for addressing co-occurring symptoms of insomnia/depression has not been tested. The purpose of this study is to evaluate the efficacy of a digital insomnia program and a digital mental health program in multiple ways: 1) as standalone interventions to reduce both symptoms of co-occurring insomnia and depression for breast cancer survivors; and 2) as components in adaptive behavioral treatment strategies that optimally sequence them for survivors who need additional support, resulting in a multifaceted supportive approach that is low cost, easily accessible, and highly efficient.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Digital Insomnia Program — A self-guided, fully automated, interactive, and tailored internet-based program modeled on the primary tenants of face-to-face CBT-I (sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, relapse prevention). It is fully accessible as a web-based application via smartphones, computers, and tablets. Content is metered out over time through six "Cores". Each Core acts as a digital analog for the typical weekly sessions of face-to-face CBT for insomnia, following the same general structure: (1) Core objectives - what will be learned and why this information is important, (2) review of previous week's homework and sleep diary data, (3) new intervention material, (4) assignment of homework - treatment strategies for the coming week, and (5) a summary of the Core's main points. Users obtain access to a new Core based on a time- and event-based schedule (i.e., time since previous Core, completion of sleep diaries).
  • Behavioral: Digital Mental Health Program — A self-guided, fully automated app designed for brief, frequent check-ins to promote skill acquisition. Exercises in the app are assigned for 1 week each, and each exercise focuses on a specific mental health target (e.g., cognitive restructuring, savoring positive experiences, increasing knowledge of mental health).
  • Behavioral: Psychoeducation — An internet delivered program that includes modules containing general health information that is not specific to mental health or insomnia. Modules contain information on the topics such as exercise and heart health,. Content is primarily text-based and contains public domain health information; that is, content that is sourced primarily from US government health websites and is non-proprietary.

Primary Outcomes

  • Patient Health-Questionnaire-8 (PHQ-8) (Baseline)
  • Patient Health Questionnaire-8 (PHQ-8) (Post 18-weeks)
  • Insomnia Severity Index (ISI) (Baseline)
  • Insomnia Severity Index (ISI) (Post 18-weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2026-09-30
Completion: 2029-08-30
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: false
Enrollment: 747 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Virginia
Collaborators: National Cancer Institute (NCI)
Contact Information
Study Contact:
Philip Chow, PhD
434-924-8082
pic2u@virginia.edu
Interventions
  • Behavioral: Digital Insomnia Program — A self-guided, fully automated, interactive, and tailored internet-based program modeled on the primary tenants of face-to-face CBT-I (sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, relapse prevention). It is fully accessible as a web-based application via smartphones, computers, and tablets. Content is metered out over time through six "Cores". Each Core acts as a digital analog for the typical weekly sessions of face-to-face CBT for insomnia, following the same general structure: (1) Core objectives - what will be learned and why this information is important, (2) review of previous week's homework and sleep diary data, (3) new intervention material, (4) assignment of homework - treatment strategies for the coming week, and (5) a summary of the Core's main points. Users obtain access to a new Core based on a time- and event-based schedule (i.e., time since previous Core, completion of sleep diaries).
  • Behavioral: Digital Mental Health Program — A self-guided, fully automated app designed for brief, frequent check-ins to promote skill acquisition. Exercises in the app are assigned for 1 week each, and each exercise focuses on a specific mental health target (e.g., cognitive restructuring, savoring positive experiences, increasing knowledge of mental health).
  • Behavioral: Psychoeducation — An internet delivered program that includes modules containing general health information that is not specific to mental health or insomnia. Modules contain information on the topics such as exercise and heart health,. Content is primarily text-based and contains public domain health information; that is, content that is sourced primarily from US government health websites and is non-proprietary.
Study Locations (1 sites)
University of Virginia, Charlottesville, Virginia 22903 United States
Eligibility Criteria
Inclusion Criteria: * (1) age ≥18 years * (2) Diagnosed with stage 0-3 breast cancer * (3) Primary treatment for cancer (i.e., chemotherapy, immunotherapy, radiation, and surgical procedures intended to remove malignant tissue) finished between 3 months to 5 years from enrollment, with the exception of adjuvant hormonal, endocrine, and immunotherapy * (4) elevated insomnia severity as measured by the Insomnia Severity Index (ISI) score ≥ 10, and elevated symptoms of depression as measured by the Patient Health Questionnaire-8 (PHQ-8) score ≥ 10 * (5) meets DSM 5 criteria for insomnia and depression. Exclusion Criteria: * (1) Current behavioral or psychological treatment for insomnia or depression * (2) a change in medication for insomnia or depression within the past 4 weeks * (3) irregular sleep schedules or shift work (i.e., usual bedtimes outside 8:00 p.m.-2:00 a.m. or arising time outside 4:00 a.m.-10:00 a.m.) * (4) mental health condition deemed to interfere with study procedures or put the participant at undue risk based on self-reported history of psychosis or bipolar disorder, or active suicidal ideation that necessitates more intense care (as indicated from the Pitt-Optimum Suicide Management Protocol) * (5) other self-reported untreated sleep disorders (i.e., obstructive sleep apnea, restless legs syndrome) * (6) no reliable internet access (e.g., home broadband, public network, personal data plan) by smartphone * (7) cannot read and speak English * (8) does not reside within the US.
Evaluation of the Effects of Aquatic Therapy on Activities of Daily Living, Walking, Balance, Posture, Pain, and Depression in Parkinson's Patients
NCT07390825
Recruiting
Conditions Parkinson Disease
Phase NA
Enrollment 42
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by motor symptoms such as bradykinesia, tremors, and postural instability, as well as various non-motor symptoms. Conventional land-based rehabilitation is standard; however, aquatherapy-utilizing water's buoyancy, hydrostatic pressure, and viscosity-offers a promising alternative to improve balance and mobility while reducing fall risks. This study aims to evaluate the effects of aquatherapy on gait, balance, posture, freezing of gait, activities of daily living (ADL), pain, and depression in Turkish PD patients. This is a prospective, single-blind, randomized controlled trial involving 42 patients at Ankara City Hospital. Participants will be divided into two groups: * Group 1 (Control): Home-based exercise program (5 days/week for 6 weeks). * Group 2 (Intervention): Home-based exercises plus supervised aquatherapy (3 sessions/week, 45 minutes each, in a 30-32°C pool). The study utilizes high-tech objective measurements and validated scales: * Gait \& Posture: Zebris Gait Analysis (spatiotemporal parameters) and Diers Formetric 4D (topographical posture analysis). * Balance: HUR-Smart Balance device and the Berg Balance Scale. * Clinical Scales: PDQ-39 (quality of life), Freezing of Gait Questionnaire, Falls Efficacy Scale, MMSE (cognitive), Beck Depression Inventory, and VAS (pain). This research is noteworthy as the first aquatherapy study among Turkish PD patients to utilize a large sample size and standardized aquatic exercise protocols. It seeks to provide a comprehensive analysis of both motor and non-motor improvements, potentially establishing aquatherapy as a superior adjunctive treatment for enhancing functional independence in Parkinson's patients. Primary hypothesis or outcome measure : Parkinson's Disease Questionnaire-39 . PDQ-39 is a patient-reported outcome measure designed to evaluate the health-related quality of life in Parkinson's patients across eight specific domains, including mobility, activities of daily living, and emotional well-being.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Aquatherapy — The specific aquatic exercise protocol for Group 2, conducted in a 120 cm deep therapy pool at 30-32°C, includes the following exercises: Gait and Mobility: Water walking (forward and backward) and side-stepping. Dynamic Balance: Forward and lateral lunges, and single-leg stance/balance drills. Lower Extremity Strengthening: Hip kicks performed at the pool wall (flexion, extension, and abduction) and standing knee raises. Upper Body and Coordination: Arm raises (multi-directional) and deep-water cycling movements. Home Exercise Component: In addition to aquatic sessions, patients will continue land-based exercises including posture correction, flexibility/stretching, balance-coordination training, and strengthening.
  • Other: home exercise — Group 1 patients will be prescribed a home exercise program at least 5 days per week for a duration of 6 weeks

Primary Outcomes

  • Parkinson's Disease Questionnaire-39 (From enrollment to the end of treatment at 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2026-08-01
Eligibility
Age: 40 Years
Sex: ALL
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ankara City Hospital Bilkent
Principal Investigators:
  • Halil Uçan, Prof. Doctor (STUDY_DIRECTOR) - Bilkent City Hospital
Contact Information
Study Contact:
Duygu Yanıktaş, MD
+905059025460
yanktasduygu@gmail.com
Interventions
  • Other: Aquatherapy — The specific aquatic exercise protocol for Group 2, conducted in a 120 cm deep therapy pool at 30-32°C, includes the following exercises: Gait and Mobility: Water walking (forward and backward) and side-stepping. Dynamic Balance: Forward and lateral lunges, and single-leg stance/balance drills. Lower Extremity Strengthening: Hip kicks performed at the pool wall (flexion, extension, and abduction) and standing knee raises. Upper Body and Coordination: Arm raises (multi-directional) and deep-water cycling movements. Home Exercise Component: In addition to aquatic sessions, patients will continue land-based exercises including posture correction, flexibility/stretching, balance-coordination training, and strengthening.
  • Other: home exercise — Group 1 patients will be prescribed a home exercise program at least 5 days per week for a duration of 6 weeks
Study Locations (2 sites)
Bilkent City Hospital, Çankaya, Ankara 06800 Turkey (Türkiye)
Bilkent City Hospital, Ankara, ÇANKAYA 06800 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Having a diagnosis of Idiopathic Parkinson's Disease between the ages of 40-80 and consenting to the treatment. * Being regularly followed by a neurologist and having a stable medical treatment regimen for at least 3 months. * Having a disease stage between 1-3 according to the Modified Hoehn-Yahr Staging Scale (MHY). * A score of 24 or higher on the Mini-Mental State Examination (MMSE). * Being able to verticalize independently and ambulate with or without assistance. Exclusion Criteria: * Having orthopedic, rheumatological, or non-Parkinson's neurological disorders that affect functional status. * Having a medical treatment regimen that has been modified within the last 3 months. * Presence of Atypical Parkinson's Disease. * Visual impairment. * Presence of dementia. * Decompensated cardiac or respiratory failure. * Diabetes insipidus. * Presence of systemic infection. * Impaired skin integrity or the presence of skin infections. * Increased sensitivity to inhaled steam or water chemicals. * History of epilepsy or asthma. * Urinary or fecal incontinence. * Refusal to participate in or consent to the treatment.
Narrative Nursing for Cesarean Mothers' Anxiety and Breastfeeding Confidence
NCT07272252
Recruiting
Conditions Postpartum Anxiety, Postpartum Depressio...
Phase NA
Enrollment 160
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study tests whether a nurse-led "4-step narrative nursing" program can reduce anxiety and improve breastfeeding confidence in mothers who are having a planned or non-emergency cesarean section. What is the problem? About 30-40% of Chinese cesarean mothers feel high anxiety after surgery, and 1 in 5 is at risk for postpartum depression. Low confidence in breastfeeding is also common. What will we do? We will randomly assign 160 mothers (1:1) to either: Usual care - standard education and ward care, or Usual care plus narrative nursing - four short (10-20 min) conversations with a trained nurse: Before surgery - help the mother talk about her fears. 24-48 h after surgery - encourage her to "name" pain or worries and separate them from herself. Before discharge - guide her to find positive moments and build a "strong-mom" story. Two weeks later by phone - strengthen the new story and review feeding success. What will we measure? Main result: anxiety score at 48 h (STAI scale). Other results: depression risk, breastfeeding confidence, pain, and feeding rates up to 3 months. Possible benefits: Lower anxiety, better mood, higher breastfeeding rates. No drugs or extra procedures are involved, only talking. Risks: Minimal; some mothers may feel emotional during conversations, but nurses can pause or refer to counselling if needed.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: 4-step narrative nursing program — Four nurse-led storytelling sessions (pre-operative externalization, post-operative deconstruction, pre-discharge reconstruction, and 2-week meaning-reconstruction phone call) aimed at reducing anxiety and increasing breastfeeding self-efficacy.

Primary Outcomes

  • Postpartum anxiety at 48 hours (48 hours post-surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2026-03-01
Eligibility
Age: 18 Years
Sex: FEMALE
Volunteers: true
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xi Huang
Collaborators: Xiamen University, Yilong People's Hospital
Contact Information
Study Contact:
X i Huang
+86-156-8090-6987
24520241154909@stu.xmu.edu.cn
Yinchun Tan
+86-152-8329-4749
2027687568@qq.com
Interventions
  • Behavioral: 4-step narrative nursing program — Four nurse-led storytelling sessions (pre-operative externalization, post-operative deconstruction, pre-discharge reconstruction, and 2-week meaning-reconstruction phone call) aimed at reducing anxiety and increasing breastfeeding self-efficacy.
Study Locations (1 sites)
Yilong County Maternal and Child Health Hospital, Nanchong, Sichuan 637600 China
Eligibility Criteria
Inclusion Criteria: 1. Women aged 18-50 years 2. Scheduled for elective or non-emergency cesarean section at ≥37 weeks 3. Able to communicate in Mandarin and provide written informed consent 4. Expected hospital stay ≥24 h 5. Singleton pregnancy with stable maternal and neonatal condition allowing routine mother-baby contact Exclusion Criteria: 1. Severe psychiatric disorders (schizophrenia, bipolar disorder, active suicidal ideation) 2. Maternal or neonatal need for ICU/NICU admission 3. Emergency cesarean section preventing baseline assessment 4. Communication or cognitive impairment precluding interview
Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS
NCT04870255
Recruiting
Conditions Depressive Disorder, Major, Borderline P...
Phase NA
Enrollment 45
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the antidepressant effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), in individuals with borderline personality disorder (BPD) or trait and comorbid mood depressive disorder (MDD) or bipolar II disorder in a current mood depressive episode (MDE).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: Left Dorsolateral Prefrontal Cortex (L-DLPFC) — Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth). Stimulation will be delivered using the Magventure Magpro X100 TMS system.
  • Device: Dorsomedial Prefrontal Cortex (DMPFC) — Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the DMPFC. Stimulation intensity will be standardized at 100% of resting motor threshold (adjusted for cortical depth). Stimulation will be delivered using the Magventure Magpro X100 TMS system.
  • Device: Sham Stimulation — Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC. Sham stimulation will be delivered using the Magventure Magpro X100 TMS system.

Primary Outcomes

  • Change in the clinician rated Montgomery-Asberg Depression Rating Scale (MADRS-C) in active L-DLPFC vs. sham aiTBS. (At baseline (pre-intervention), during the intervention and immediately after the intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-07-20
Completion: 2026-12
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Principal Investigators:
  • David Spiegel, MD (STUDY_DIRECTOR) - Stanford University
Contact Information
Study Contact:
Bora Kim, MD, MAS
650-800-6929
borakim2@stanford.edu
Nick Bassano, MSW
650-800-6929
nbassano@stanford.edu
Interventions
  • Device: Left Dorsolateral Prefrontal Cortex (L-DLPFC) — Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the left DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth). Stimulation will be delivered using the Magventure Magpro X100 TMS system.
  • Device: Dorsomedial Prefrontal Cortex (DMPFC) — Participants who are randomly assigned to this group will receive active iTBS (intermittent theta burst stimulation) to the DMPFC. Stimulation intensity will be standardized at 100% of resting motor threshold (adjusted for cortical depth). Stimulation will be delivered using the Magventure Magpro X100 TMS system.
  • Device: Sham Stimulation — Participants who are randomly assigned to this group will receive sham stimulation to the left DLPFC. Sham stimulation will be delivered using the Magventure Magpro X100 TMS system.
Study Locations (1 sites)
Stanford Hospital, Stanford, California 94305 United States
Eligibility Criteria
Inclusion Criteria: * Male or Female, between the ages of 18 and 80 at the time of screening. * Able to read, understand, and provide written, dated informed consent prior to screening. Proficiency in English sufficient to complete questionnaires / follow instructions during fMRI assessments and aiTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information. * Diagnosed with Major Depressive Disorder (MDD) or Bipolar II, or unspecified depressive disorder AND Borderline Personality Disorder or trait, with a current Mood Depressive Episode (MDE), according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5). * MADRS score of ≥20 at screening (Visit 1). * TMS naive. * Access to ongoing psychiatric care before and after completion of the study. * Access to clinical rTMS after study completion. * In good general health, as evidenced by medical history. * For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation. * Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration. Exclusion Criteria: * Pregnancy * The presence or diagnosis of prominent anxiety disorder, personality disorder, or dysthymia * Current severe insomnia (must sleep a minimum of 5 hours each night before stimulation) * Current mania or psychosis * Bipolar I Disorder and primary psychotic disorders. * Autism Spectrum disorder or Intellectual Disability * A diagnosis of obsessive-compulsive disorder (OCD) * Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal. * Urine screening test positive for illicit substances. * Any history of ECT (greater than 8 sessions) without meeting responder criteria * Recent (during the current depressive episode) or concurrent use of a rapid acting antidepressant agent (i.e., ketamine or a course of ECT). * History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, unexpected seizure/epilepsy disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma. * Untreated or insufficiently treated endocrine disorder. * Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion) * Contraindications to MRI (ferromagnetic metal in their body). * Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation. * Depth-adjusted aiTBS treatment dose \> 65% maximum stimulator output (MSO) * Treatment with another investigational drug or other intervention within the study period. * Any other condition deemed by the PI to interfere with the study or increase risk to the participant.
Therapy and Tech Study
NCT07225192
Not yet recruiting
Conditions Generalized Anxiety Disorder (GAD), Majo...
Phase NA
Enrollment 204
Locations 0 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The investigators want to test if gen AI can support therapy by recruiting patients already in therapy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Chatbot Therapy — This group will be asked to use an AI chatbot like chatgpt as an adjunct to their regular therapy

Primary Outcomes

  • Generalized Anxiety Disorder (GAD-7) (Baseline, 4-week follow-up, 8-week follow-up)
  • Patient Health Questionnaire (PHQ-9) (Baseline, 4-week follow-up, 8-week follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Not yet recruiting
Start Date: 2025-11
Completion: 2026-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 204 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Irvine
Collaborators: National Center for Complementary and Integrative Health (NCCIH)
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Behavioral: Chatbot Therapy — This group will be asked to use an AI chatbot like chatgpt as an adjunct to their regular therapy
Eligibility Criteria
Inclusion Criteria: * 18+ * US Resident * English-speaking * Self-report having been treated for or diagnosed with generalized anxiety disorder or major depressive disorder by a licensed provider (e.g., MD, DO, LPCC, LCSW, LMFT) in the past 12 months * Self-report currently being in individual therapy Exclusion Criteria: * Ever diagnosed with schizophrenia, schizoaffective disorder, bipolar disorder, or hospitalized for suicidality
Comparison of Remimazolam and Propofol in Endoscopic Examinations and Treatments
NCT06777758
Recruiting
Conditions Postoperative Complications, Respiratory...
Phase PHASE4
Enrollment 90
Locations 1 sites
Compensation Phase 4: Typically $100-$500
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the efficacy and safety of Remimazolam, either used alone or in combination with Propofol, for moderate sedation anesthesia during endoscopic therapies or examinations. Additionally, it seeks to explore whether their combination can further enhance the quality of patient anesthesia and recovery outcomes.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Remimazolam — Remimazolam
  • Drug: Propofol — Propofol dose reduction ratio

Primary Outcomes

  • Dose change (Perioperatively (during upper gastrointestinal endoscopy))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-02-12
Completion: 2026-12-31
Eligibility
Age: 20 Years
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kaohsiung Veterans General Hospital.
Principal Investigators:
  • CHIA-HAO YANG, M.D (PRINCIPAL_INVESTIGATOR) - employe
  • Tzung-Jim Tsai, M.D (PRINCIPAL_INVESTIGATOR) - employe
Contact Information
Study Contact:
Yuan-Yi Chia, M.D
886-7-342-2121
yychia@vghks.gov.tw
Chen-Hsiu Chen, Ph.D
886-7-342-2121
chschen@vghks.gov.tw
Interventions
  • Drug: Remimazolam — Remimazolam
  • Drug: Propofol — Propofol dose reduction ratio
Study Locations (1 sites)
Kaohsiung Veterans General Hospital, Kaohsiung City, 81362 Taiwan
Eligibility Criteria
Inclusion Criteria: * Subjects are between 20-80 years old. * Anesthesiologists rated ASA as between I and III. * Patients undergoing upper gastrointestinal endoscopic examination or therapy. Exclusion Criteria: * Allergy to Propofol, Remimazolam, or opioid medications. * Emergency surgery. * Pregnancy. * History of malignant hyperthermia. * Impaired liver or kidney function. * Airway difficulties due to pharyngeal tumors. * Refusal to participate.
Ketamine Treatment Plans for Chronic Conditions
NCT06038409
Recruiting
Conditions Chronic Pain, Depressive Disorder, Anxie...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Compensation varies
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

A study aimed to assess the efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the study plan of those with chronic conditions who are receiving ketamine.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Drug: Ketamine — The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions

Primary Outcomes

  • Ketamine route of use acceptability. (through study completion, an average of 1 year)
  • Mental Health PHQ9 (through study completion, an average of 1 year)
  • Mental Health GAD7 (through study completion, an average of 1 year)
  • Mental Health PCL5 (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-01
Completion: 2029-06-01
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RIVER Foundation
Principal Investigators:
  • Edward Lesofski, MS (STUDY_DIRECTOR) - RIVER Foundation
Contact Information
Study Contact:
Ed Lesofski
406-465-9504
ed@riverofchange.org
James Taggart, MD
415-713-6654
jrtaggartmd@aol.com
Interventions
  • Drug: Ketamine — The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions
Study Locations (1 sites)
RIVER Telehealth, Helena, Montana 59601 United States
Eligibility Criteria
Inclusion Criteria: Must have an identifiable chronic condition. Exclusion Criteria: Healthy population
Meditation Accelerated Brain Stimulation for Depression
NCT04586699
Active, positions filled
Conditions Depression
Phase NA
Enrollment 50
Locations 2 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

Repetitive Transcranial magnetic stimulation (rTMS) is an FDA-approved treatment for depression that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. The ultimate goal of this treatment is to increase excitability and long-term plasticity in DLPFC, a brain region shown to be hypo-active in depression. Unfortunately, rTMS only has low to moderate efficacy; remission rates for patients range from \~15-30% in large randomized controlled trials. The focus of this research is to develop a next-generation rTMS protocol that is guided by the basic principles underlying brain plasticity, in order to improve the efficacy of rTMS for the treatment of depression. Specifically, in this study the investigators will test rTMS paired with a depression-relevant cognitive state of internal attention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Medi1TMS — rTMS theta-burst protocol paired with a consistent attention-to-breath task
  • Device: Medi2TMS — rTMS theta-burst protocol paired with an intermittent deep breathing task

Primary Outcomes

  • Change from baseline Clinical Depression (Remission) (up to 6 weeks)
  • Change from baseline brain activity in attention-to-breath task (up to 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Active, positions filled
Start Date: 2021-07-15
Completion: 2026-06-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Principal Investigators:
  • Jyoti Mishra, PhD (PRINCIPAL_INVESTIGATOR) - University of California, San Diego
Contact Information
No direct contact listed - use the ClinicalTrials.gov link below to reach the study team
Interventions
  • Device: Medi1TMS — rTMS theta-burst protocol paired with a consistent attention-to-breath task
  • Device: Medi2TMS — rTMS theta-burst protocol paired with an intermittent deep breathing task
Study Locations (2 sites)
Neuromodulation Clinic Veterans Affairs San Diego, San Diego, California 92037 United States
UC San Diego Health Psychiatry, San Diego, California 92127 United States
Eligibility Criteria
Inclusion Criteria: * moderate to severe depression (PHQ-9 scale score \>9 with confirmation using the Structured Clinical Interview for DSM-5 Disorders) * treatment refractory to antidepressants (i.e. failed 1-3 antidepressants in current episode) or intolerant to antidepressants (i.e. tried 2 antidepressant of inadequate dose/duration in current episode) Exclusion Criteria: * active substance abuse/dependence * psychotic disorders * any factor that increases risk of TMS (metal implants/history of stroke/seizure disorder). * displaying acutely suicidal behaviors on the Columbia Suicide Severity Rating Scale.
The Impact of Low Sodium Salt Substitute Use on Serum Potassium Levels Among Patients With Hypertension
NCT07460882
Recruiting
Conditions Hypertension
Phase NA
Enrollment 607
Locations 1 sites
Compensation Compensation typically provided
Data Updated 2026-09-11
Click to view full details
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this pre-post study is to assess the risk of hyperkalemia in adults with hypertension on medication in Bangladesh. The main questions it aims to answer are: Is the risk of hyperkalemia after the initiation of Low Sodium Salt Substitute (LSSS) in people on antihypertensive medication (especially RASi) large enough to be concerned about its broad use in this population? Does initiation of LSSS correct hypokalemia in people on antihypertensive medication (especially RASi) with low serum potassium levels? Participants will be asked to reduce overall salt intake and to use LSSS on every occasion where regular salt would normally be used, including as cooking salt.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Low-sodium salt substitute — The low sodium salt substitute contains 25% potassium chloride (KCl range; 20%-35%)

Primary Outcomes

  • Incident hyperkalemia (K ≥5.5 mmol/L) (4 and 8 weeks)
  • Proportion of the correction of hypokalemia (from K <3.5 mmol/L to 3.5-5.0 mmol/L) (4 and 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-08
Completion: 2027-09-30
Eligibility
Age: 18 Years
Sex: ALL
Volunteers: false
Enrollment: 607 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: National Heart Foundation of Bangladesh, Vital Strategies
Principal Investigators:
  • Junichi Ishigami, MD, PhD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins University
Contact Information
Study Contact:
Junichi Ishigami, MD, PhD
14432877262
jishiga1@jhu.edu
Sohel Reza Choudhury, MD, PhD
Interventions
  • Dietary Supplement: Low-sodium salt substitute — The low sodium salt substitute contains 25% potassium chloride (KCl range; 20%-35%)
Study Locations (1 sites)
The National Heart Foundation of Bangladesh, Dhaka, Bangladesh
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 years with clinically diagnosed hypertension treated with medication \[on a stable dose at least for 2 months\] * Have a phone for contact Exclusion Criteria: * Those with baseline K ≥5.0 or K \<3.0 mmol/L * Advanced kidney disease (eGFR \<45 ml/min/1.73m2). * Those on potassium sparing diuretics (e.g., spironolactone) * Other medical conditions determined by physicians (e.g., heart failure treated with medication; life expectancy less than 12 months) * Dine out for dinner more than 3 times a week